These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18634833)

  • 21. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's disease.
    Patel D; Xu C; Nagarajan S; Liu Z; Hemphill WO; Shi R; Uversky VN; Caldwell GA; Caldwell KA; Witt SN
    Hum Mol Genet; 2018 May; 27(9):1514-1532. PubMed ID: 29452354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft.
    Park JY; Kim KS; Lee SB; Ryu JS; Chung KC; Choo YK; Jou I; Kim J; Park SM
    J Neurochem; 2009 Jul; 110(1):400-11. PubMed ID: 19457104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein Decreases the Abundance of Proteasome Subunits and Alters Ubiquitin Conjugates in Yeast.
    Popova B; Galka D; Häffner N; Wang D; Schmitt K; Valerius O; Knop M; Braus GH
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis.
    Soper JH; Kehm V; Burd CG; Bankaitis VA; Lee VM
    J Mol Neurosci; 2011 Mar; 43(3):391-405. PubMed ID: 20890676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.
    Yahi N; Di Scala C; Chahinian H; Fantini J
    Glycoconj J; 2022 Feb; 39(1):1-11. PubMed ID: 34328594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. alpha-synuclein and Parkinson's disease: the first roadblock.
    Chua CE; Tang BL
    J Cell Mol Med; 2006; 10(4):837-46. PubMed ID: 17125588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson's disease.
    Gade VR; Kardani J; Roy I
    Int J Biochem Cell Biol; 2014 Oct; 55():87-92. PubMed ID: 25161148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
    Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
    Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel protein phosphatases as modifiers of alpha-synuclein aggregation in yeast.
    Brás IC; Tenreiro S; Silva AM; Outeiro TF
    FEMS Yeast Res; 2018 Dec; 18(8):. PubMed ID: 30277516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of Gem1 (mammalian Miro/Rhot) mitigates alpha-synuclein toxicity in a yeast model of Parkinson's disease.
    Melo TQ; Palma FR; Gomes F; Netto LES; Ferrari MFR
    Mol Cell Neurosci; 2022 Sep; 122():103757. PubMed ID: 35843531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased copper toxicity in Saccharomyces cerevisiae lacking VPS35, a component of the retromer and monogenic Parkinson disease gene in humans.
    Sowada N; Stiller B; Kubisch C
    Biochem Biophys Res Commun; 2016 Aug; 476(4):528-533. PubMed ID: 27262440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.
    Lee JT; Wheeler TC; Li L; Chin LS
    Hum Mol Genet; 2008 Mar; 17(6):906-17. PubMed ID: 18065497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of copy number on α-synuclein's toxicity and its protective role in Bax-induced apoptosis, in yeast.
    Akintade DD; Chaudhuri B
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32794578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benefits of humanized yeast models to study Parkinson's disease.
    Franssens V; Bynens T; Van den Brande J; Vandermeeren K; Verduyckt M; Winderickx J
    Oxid Med Cell Longev; 2013; 2013():760629. PubMed ID: 23936613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.